Therapeutics of X-linked hypophosphatemic rickets
- 1 December 1993
- journal article
- review article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 7 (6) , 744-748
- https://doi.org/10.1007/bf01213343
Abstract
X-linked hypophosphatemia, the most common form of familial rickets, is conventionally treated with 1,25-dihydroxyvitamin D3 (5–50 ng/kg per day) plus phosphate supplementation (70–100 mg/kg per day). However, nephrocalcinosis is noted in many children treated with this therapy. Whether to treat or not and whether such treatment should be continued into adulthood or in pregnancy are unsettled questions. This article reviews these controversies and provides current recommendations.Keywords
This publication has 34 references indexed in Scilit:
- Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouseThe Journal of Pediatrics, 1992
- The pattern of growth and growth retardation of patients with hypophosphataemic vitamin D-resistant rickets: A longitudinal studyEuropean Journal of Pediatrics, 1992
- Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: Influence of treatment regimen and parental heightThe Journal of Pediatrics, 1990
- Intramyocellular phosphate metabolism in X-linked hypophosphatemic ricketsThe Journal of Pediatrics, 1990
- Nephrocalcinosis and its relationship to treatment of hereditary ricketsThe Journal of Pediatrics, 1987
- Renal hypophosphatemic ricketsThe Journal of Pediatrics, 1985
- Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1α-hydroxyvitamin D3The Journal of Pediatrics, 1981
- Bone Response to Phosphate Salts, Ergocalciferol, and Calcitriol in Hypophosphatemic Vitamin D-Resistant RicketsNew England Journal of Medicine, 1980
- X-LINKED HYPOPHOSPHATÆMIC RICKETS: INADEQUATE THERAPEUTIC RESPONSE TO 1,25-DIHYDROXYCHOLECALCIFEROLThe Lancet, 1973
- Lesion of the Bone Matrix in Vitamin D-resistant RicketsNature, 1965